CopyMark Law Group
4.9/5
Drawing for EPISCREEN

USPTO serial 86716415

EPISCREEN

Reviewed by CopyMark Law Group

Reg. 5093688Status 704Renewal
Filing date
Status date
Registration date
Dec 6, 2016
Examiner
CARROLL, DORITT
Law office
—

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 704: Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active.

Need help with EPISCREEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*

Plus Government fees of $1,300

Trademark Monitoring(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joyce von Natzmer

Joyce von Natzmer Agris & von Natzmer LLP43 West 43rd Street, Suite 104New York, NY 10036UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceuticals and pharmaceutical preparations used to treat cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; chemical preparations for medical or pharmaceutical purposes, namely, chemicals sold as integral component parts of pharmaceutical preparations for the treatment of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; chemico-pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; vaccines; pharmaceutical preparations for skin care ]SECTION 8 - CANCELLED—
042Scientific research and product development services in relation to pharmaceutical and medical products; pharmaceutical research services; pharmaceutical product evaluation; testing of pharmaceuticals, namely, assessing the potential immunogenicity of proteins and antibodies by measuring immune cell responses to the pharmaceutical; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the fields of cancer, diseases and disorders of the immune system, viral diseases and disorders, inflammatory diseases, fibrotic diseases, pulmonary diseases, gastro-intestinal diseases and disorders, haematological diseases and disorders, neurological diseases and disorders, pain, obesity, diabetes and graft rejection; toxicology services; provision of scientific information relating to the chemical industry, namely, information on the subject of chemical product developmentACTIVE—
044Medical services, namely, providing medical information regarding pharmaceuticals; Pharmacy and health advice; pharmaceutical services and provision of pharmaceutical information, all in the nature of providing medical information regarding pharmaceuticals; Medical screening; Medical screening to assess the potential immunogenicity of therapeutic antibodies and proteinsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 6, 2025REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 30, 2023NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Sep 30, 20238.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
Sep 22, 2023EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Jun 2, 2023PRA8POST REGISTRATION ACTION MAILED - SEC. 8—
Jun 2, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 2, 2022ES8RTEAS SECTION 8 RECEIVED—
Dec 6, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 31, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 6, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 31, 2016DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Oct 30, 2016AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 11, 2016IUCNNOTICE OF ALLOWANCE CANCELLED—
Oct 11, 2016EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Aug 23, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 28, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 28, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 8, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 20, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 13, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 5, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 5, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 28, 2016ALIEASSIGNED TO LIE—
Apr 15, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 19, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 19, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 19, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 18, 2015DOCKASSIGNED TO EXAMINER—
Aug 11, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 10, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance